Pneumonitis with amivantamab in squamous cell lung cancer with EGFR exon 20 insertion mutation: a case report

[1] Park K, Haura EB, Leighl NB, et al.: Amivantamab in EGFR Exon 20 Insertion-Mutated Non-Small-Cell Lung Cancer Progressing on Platinum Chemotherapy: Initial Results From the CHRYSALIS Phase I Study. J Clin Oncol. 2021, 39:3391–3402. 10.1200/JCO.21.00662. ParkK HauraEB LeighlNB Amivantamab in EGFR Exon 20 Insertion-Mutated Non-Small-Cell Lung Cancer Progressing on Platinum Chemotherapy: Initial Results From the CHRYSALIS Phase I Study J Clin Oncol 2021 39 3391 3402 10.1200/JCO.21.00662 Open DOISearch in Google Scholar

[2] Xie Y, Lu Q, Wang JQ, Bo L, Ashby CR Jr, Chen ZS: Amivantamab: a monoclonal EGFR-MET bispecific antibody for EGFR exon 20 insertion in non-small cell lung cancer. Drugs Today (Barc. 2022, 58:389–398. 10.1358/dot.2022.58.8.3432777. XieY LuQ WangJQ BoL AshbyCRJr ChenZS Amivantamab: a monoclonal EGFR-MET bispecific antibody for EGFR exon 20 insertion in non-small cell lung cancer Drugs Today (Barc 2022 58 389 398 10.1358/dot.2022.58.8.3432777 Open DOISearch in Google Scholar

[3] National Comprehensive Cancer Network. Clinical Practice Guidelines in Oncology. Non-Small Cell Lung Cancer (Version 2.2024 - February 9). (2024). Accessed: 2 March, 2024: https://www.nccn.org/professionals/physician_gls/pdf/nscl.pdf. National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology. Non-Small Cell Lung Cancer (Version 2.2024 - February 9) 2024 Accessed: 2 March, 2024: https://www.nccn.org/professionals/physician_gls/pdf/nscl.pdf. Search in Google Scholar

[4] Zhou C, Ramalingam SS, Kim TM, et al.: Treatment Outcomes and Safety of Mobocertinib in Platinum-Pretreated Patients With EGFR Exon 20 Insertion-Positive Metastatic Non-Small Cell Lung Cancer: A Phase 1/2 Open-label Nonrandomized Clinical Trial [published correction appears in. JAMA Oncol. 202224, 2022:1359–2021. 10.1001/jamaoncol.2021.4761. ZhouC RamalingamSS KimTM Treatment Outcomes and Safety of Mobocertinib in Platinum-Pretreated Patients With EGFR Exon 20 Insertion-Positive Metastatic Non-Small Cell Lung Cancer: A Phase 1/2 Open-label Nonrandomized Clinical Trial [published correction appears in JAMA Oncol 202224 2022 1359 2021 10.1001/jamaoncol.2021.4761 Open DOISearch in Google Scholar

[5] Arcila ME, Nafa K, Chaft JE, et al.: EGFR exon 20 insertion mutations in lung adenocarcinomas: prevalence, molecular heterogeneity, and clinicopathologic characteristics. Mol Cancer Ther. 2013, 12:220–229. 10.1158/1535-7163.MCT-12-0620. ArcilaME NafaK ChaftJE EGFR exon 20 insertion mutations in lung adenocarcinomas: prevalence, molecular heterogeneity, and clinicopathologic characteristics Mol Cancer Ther 2013 12 220 229 10.1158/1535-7163.MCT-12-0620 Open DOISearch in Google Scholar

[6] DerSarkissian M, Li S, Galaznik A, et al.: HSR19-084: Real-World Treatment Patterns and Clinical Outcomes in Non-Small Cell Lung Cancer Patients with EGFR Exon 20 Insertion Mutations. J Natl Compr Canc Netw. 2019, 17:19–084. 10.6004/jnccn.2018.7200. DerSarkissianM LiS GalaznikA HSR19-084: Real-World Treatment Patterns and Clinical Outcomes in Non-Small Cell Lung Cancer Patients with EGFR Exon 20 Insertion Mutations J Natl Compr Canc Netw 2019 17 19 084 10.6004/jnccn.2018.7200 Open DOISearch in Google Scholar

[7] Van Sanden S, Murton M, Bobrowska A, et al.: Prevalence of Epidermal Growth Factor Receptor Exon 20 Insertion Mutations in Non-small-Cell Lung Cancer in Europe: A Pragmatic Literature Review and Meta-analysis. Target Oncol. 2022, 17:153–166. 10.1007/s11523-022-00868-z. Van SandenS MurtonM BobrowskaA Prevalence of Epidermal Growth Factor Receptor Exon 20 Insertion Mutations in Non-small-Cell Lung Cancer in Europe: A Pragmatic Literature Review and Meta-analysis Target Oncol 2022 17 153 166 10.1007/s11523-022-00868-z Open DOISearch in Google Scholar

[8] Garrido P, Girard N, Cho B, et al.: Long-term efficacy, safety and predictors of response to amivantamab among patients with post-platinum EGFR ex20ins-mutated advanced NSCLC. 29-1. GarridoP GirardN ChoB Long-term efficacy, safety and predictors of response to amivantamab among patients with post-platinum EGFR ex20ins-mutated advanced NSCLC. 29-1 Search in Google Scholar

[9] Zhou C, Tang KJ, Cho BC, et al.: Amivantamab plus Chemotherapy in NSCLC with EGFR Exon 20 Insertions. N Engl J Med. 2023, 389:2039–2051. 10.1056/NEJMoa2306441. ZhouC TangKJ ChoBC Amivantamab plus Chemotherapy in NSCLC with EGFR Exon 20 Insertions N Engl J Med 2023 389 2039 2051 10.1056/NEJMoa2306441 Open DOISearch in Google Scholar

[10] Passaro A, Wang J, Wang Y, et al.: Amivantamab plus chemotherapy with and without lazertinib in EGFR-mutant advanced NSCLC after disease progression on osimertinib: primary results from the phase III MARIPOSA-2 study. Ann Oncol. 2024, 35:77–90. 10.1016/j.annonc.2023.10.117. PassaroA WangJ WangY Amivantamab plus chemotherapy with and without lazertinib in EGFR-mutant advanced NSCLC after disease progression on osimertinib: primary results from the phase III MARIPOSA-2 study Ann Oncol 2024 35 77 90 10.1016/j.annonc.2023.10.117 Open DOISearch in Google Scholar